Britain and America have finalized a key trade agreement that will maintain no duties on UK pharmaceutical shipments going into the US market.
Key Provisions of the Pact
As part of the deal, the UK has agreed to boost funding on drugs through the NHS. This move secures that duties on these crucial goods will remain at nothing for a timeframe of the next three years.
This deal follows earlier threats to hike tariffs on branded drug imports, with potential rates mentioned as high as double the cost.
"This agreement between the Britain reinforces the global environment for innovative medicines and establishes long-overdue fairness to transatlantic drug exports," an announcement said.
Trade Importance
Drugs constitute one of the Britain's largest export categories to the America, which is easily the primary market for major British pharmaceutical firms.
Trade data indicate that in the one-year period to the end of the third quarter, the UK sold medicines worth £11.1bn to the US. This figure made up 17.4% of total UK exports in that period.
"This deal secures work, boosts funding and paves the way for the UK to emerge as a worldwide center for biotech and pharma," a government official stated.
Key British Pledges
The pact includes several notable pledges from the UK:
- Price Threshold Increase: The UK will lift the affordability limit at which it considers new therapies to be unaffordable by 25%.
- Boosted Medicine Funding: There is a goal to double overall NHS spending on medicines from 0.3% of GDP to 0.6 percent over the coming ten years.
- Payback Limit: The sum manufacturers must return to the NHS to stay within budget will be limited at fifteen percent. Previously, refunds were more than 20%.
Broader Context
The pact takes place against a protracted row between the pharmaceutical industry and the British authorities over medicine costs and approval rates.
These tensions were exacerbated by arguments that American patients were charged a premium for the same drugs than people in the UK and Europe.
Over the last 18 months, several large drug company projects in the UK have been delayed or scrapped, while multi-billion-dollar expansions have been announced toward American operations.
One official publicly accepted that the NHS must increase expenditure on treatments, noting that its spending on drugs had declined as a share of its total funding over the last ten years.
